AGM/EGMJul 10, 2026, 05:17 PM
Cellectar Stockholders Approve 2M Share Increase for Stock Plan, Warrant Exercise
AI Summary
Cellectar Biosciences, Inc. held its Annual Meeting of Stockholders on July 7, 2026, where several key proposals were approved. Stockholders voted to increase the number of shares reserved for issuance under the 2021 Stock Incentive Plan by 2,000,000 shares. Additionally, the exercise of warrants to purchase up to 39,618,078 shares of common stock was approved. Directors Andrew Gu and Douglas J. Swirsky were elected, Deloitte & Touche LLP was ratified as the auditor, and executive officer compensation was approved.
Key Highlights
- Stockholders approved an increase of 2,000,000 shares for the 2021 Stock Incentive Plan.
- Andrew Gu and Douglas J. Swirsky were elected as Class III directors for three-year terms.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2026.
- Executive officer compensation was approved on a non-binding advisory basis.
- Stockholders approved the exercise of warrants for up to 39,618,078 shares of common stock.
Price Impact
More from CLRB